SCHEDULE: Immuneering Insider Zeskind Reports 6.6% Stake

Benjamin J. Zeskind, a key insider at Immuneering Corporation, has reported beneficial ownership of 6.6% of the company's Class A common stock as of December 31, 2025.

Summary

• Benjamin J. Zeskind beneficially owns 4,357,807 shares of Immuneering Corporation's Class A common stock.
• This ownership represents 6.6% of the total Class A common stock outstanding.
• The beneficial ownership includes 2,312,852 shares held directly by Mr. Zeskind, 1,150,028 shares underlying stock options exercisable on or prior to March 1, 2026, and 894,927 shares held by the Benjamin J. Zeskind 2020 Family Trust.
• The percentage of class is calculated based on 64,569,967 shares of Class A Common Stock outstanding as of November 5, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q.

Sentiment

Score: 7

Explanation: The filing indicates a significant beneficial ownership stake by a key insider, Benjamin J. Zeskind, which can be interpreted as a positive signal of confidence in the company's future.

Positives

• A significant beneficial ownership stake by a key insider like Benjamin J. Zeskind can signal confidence in the company's future prospects.
• The inclusion of 1,150,028 shares from exercisable stock options indicates potential future exercise and a long-term commitment to the company.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

This filing is a routine disclosure of beneficial ownership by an insider and does not provide information related to broader industry trends or competitors.

Related Party Transactions

• The filing discloses that 894,927 shares are held by the Benjamin J. Zeskind 2020 Family Trust, where the Reporting Person's spouse serves as sole trustee, constituting a related party holding.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant insider's ownership stake, which can influence investor sentiment and perception of management alignment.

Key Dates

Recommendation

While a significant insider stake can be a positive signal of confidence, a Schedule 13G filing primarily provides ownership disclosure and lacks the comprehensive financial or operational details needed for a strong buy or sell recommendation. It suggests alignment of interests but does not provide new fundamental data to change a prior investment thesis. Therefore, a 'hold' recommendation is appropriate, pending further operational or financial updates.

Keywords

Immuneering Corporation, Benjamin J. Zeskind, Class A common stock, Beneficial ownership, Insider ownership, SEC filing, Schedule 13G, Equity stake